Company Performance Metrics
MangoGen Pharma aims to develop gene-delivering medical devices that improve human health. It has its headquarters in Laval in Quebec in Canada, and owns a novel patented technology developed by Professor Satya Prakash at McGill University that utilizes genetically modified baculoviruses encapsulated (to protect from serum inactivation) and coated
on to medical devices. On device deployment, the virus enters the local cells, delivers the human gene, and an active protein is expressed. MangoGen’s product pipeline includes the development of gene-delivering coronary stent (the next generation of stents), a gene-delivering film-dressing to promote and accelerate wound healing (e.g. for diabetic foot ulcers), and gene-delivering sutures. Professor Satya Prakash, Doctorr Paul Plested, Doctor Dominique Shum-Tim and Doctor Arghya Paul founded it. MangoGen’s patented technology utilizes a novel approach of using baculovirus encapsulated in a biodegradable coating that is coated onto a coronary stent, or a film-dressing or suture.
